ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 431,04
-0,79%
Dow Jones
41 938,45
-1,63%
DAX
20 214,79
-0,51%
Brent Oil
79,285
0,00%
Bitcoin
94 498,29
-0,08%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Context Therapeutics Inc (CNTX) Cours

Context Therapeutics Inc

Context Therapeutics Inc (CNTX)

NASDAQ
1,08
-0,13
(-10,74%)
Fermé 12 Janvier 10:00PM
Retardé de 15 minutes
1,08
0,00
(0,00%)
Après les heures de négociation: 1:50AM
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
1,08
Prix Achat
1,08
Prix Vente
1,11
Volume échangé
263 467
1,06 Fourchette du Jour 1,29
0,89 Plage de 52 semaines 2,75
Cap du marché
80,998M
Clôture Veille
1,21
Ouverture
1,23
Dernière Transaction
395
@
1.08
(formt)
Dernière heure de transaction
Volume financier
US$ 294 827
VWAP
1,119
Volume moyen (3 m)
571 231
Actions en circulation
74 998 312
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-3,38
Bénéfice par action (BPA)
-0,32
Chiffre d'affairess
-
Bénéfice net
-23,96M

À propos de Context Therapeutics Inc

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics with multiple products in development, including two clinical-stage assets. Con... Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics with multiple products in development, including two clinical-stage assets. Context is headquartered in Philadelphia. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.contexttherapeutics.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Context Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker CNTX. Le dernier cours de clôture d'Context Therapeutics était de US$1,21. Au cours de la dernière année, les actions de Context Therapeutics ont été négociées dans une fourchette de prix de US$ 0,89 à US$ 2,75.

Context Therapeutics compte actuellement 74 998 312 actions en circulation. La capitalisation boursière d'Context Therapeutics est de US$90,75 million. Context Therapeutics a un ratio cours/bénéfice (ratio PE) de -3.38.

CNTX Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

23 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

02 Décembre 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

02 Décembre 2024
Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness

15 Novembre 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

14 Novembre 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

06 Novembre 2024
Edgar (US Regulatory)

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody Strengthens board...

06 Novembre 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

06 Novembre 2024
Edgar (US Regulatory)

Context Therapeutics to Participate in Upcoming Investor Conferences in November

PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today...

23 Octobre 2024
GlobeNewswire Inc.

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today...

16 Octobre 2024
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.22-16.92307692311.31.31.083054321.19745714CS
4-0.37-25.51724137931.451.470.941112505761.02903193CS
12-0.93-46.26865671642.012.58990.94115712311.32543835CS
26-0.97-47.31707317072.052.750.94113494781.53159491CS
52-0.17-13.61.252.750.893713801.67350829CS
156-1.34-55.37190082642.422.790.474115401.41344522CS
260-3.36-75.67567567574.4410.870.477535393.61319881CS

CNTX - Frequently Asked Questions (FAQ)

What is the current Context Therapeutics share price?
The current share price of Context Therapeutics is US$ 1,08
How many Context Therapeutics shares are in issue?
Context Therapeutics has 74 998 312 shares in issue
What is the market cap of Context Therapeutics?
The market capitalisation of Context Therapeutics is USD 90,75M
What is the 1 year trading range for Context Therapeutics share price?
Context Therapeutics has traded in the range of US$ 0,89 to US$ 2,75 during the past year
What is the PE ratio of Context Therapeutics?
The price to earnings ratio of Context Therapeutics is -3,38
What is the reporting currency for Context Therapeutics?
Context Therapeutics reports financial results in USD
What is the latest annual profit for Context Therapeutics?
The latest annual profit of Context Therapeutics is USD -23,96M
What is the registered address of Context Therapeutics?
The registered address for Context Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Context Therapeutics website address?
The website address for Context Therapeutics is www.contexttherapeutics.com
Which industry sector does Context Therapeutics operate in?
Context Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
VRMEVerifyMe Inc
US$ 2,57
(52,98%)
57,7M
WKEYWISeKey International Holdings AG
US$ 10,041
(52,83%)
6,69M
DATSDatChat Inc
US$ 4,8105
(49,86%)
158,56M
CDTConduit Pharmaceuticals Inc
US$ 0,1214
(48,05%)
1,16B
INTZIntrusion Inc
US$ 2,8888
(44,44%)
40,45M
IGMSIGM Biosciences Inc
US$ 2,095
(-66,21%)
5,69M
CDTGCDT Environmental Technology Investment Holdings Ltd
US$ 1,87
(-51,30%)
2,28M
MODVModivCare Inc
US$ 6,51
(-47,88%)
2,73M
AIFUAIX Inc
US$ 0,420501
(-47,76%)
7,83M
MRSNMersana Therapeutics Inc
US$ 0,691
(-46,85%)
58,31M
CDTConduit Pharmaceuticals Inc
US$ 0,1214
(48,05%)
1,16B
NVDANVIDIA Corporation
US$ 135,91
(-3,00%)
203,27M
RGTIRigetti Computing Inc
US$ 8,9299
(-11,06%)
175,21M
VMARVision Marine Technologies Inc
US$ 2,14
(40,79%)
174,99M
DATSDatChat Inc
US$ 4,8105
(49,86%)
158,56M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
CNTX
Context Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés